{"id":593,"date":"2025-10-06T12:00:26","date_gmt":"2025-10-06T12:00:26","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/10\/06\/ectrims-2025-briumvi-keeps-ms-patients-relapse-free-for-6-years\/"},"modified":"2025-10-06T12:00:26","modified_gmt":"2025-10-06T12:00:26","slug":"ectrims-2025-briumvi-keeps-ms-patients-relapse-free-for-6-years","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/10\/06\/ectrims-2025-briumvi-keeps-ms-patients-relapse-free-for-6-years\/","title":{"rendered":"ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/ectrims\/2025\/10\/06\/ectrims-2025-briumvi-keeps-ms-patients-relapse-free-6-years\/\" title=\"ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"293\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2024\/09\/ECTRIMS-2-800x293.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"A presenter at ECTRIMS speaks to an audience joining in the conference virtually.\" style=\"margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"142311\" \/><\/a><\/p>\n<p>Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/ectrims\/2025\/10\/06\/ectrims-2025-briumvi-keeps-ms-patients-relapse-free-6-years\/\">ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/ectrims\/2025\/10\/06\/ectrims-2025-briumvi-keeps-ms-patients-relapse-free-6-years\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of [&#8230;] The post ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com<\/p>\n","protected":false},"author":0,"featured_media":594,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-593","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=593"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/593\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/594"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}